EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comprehensive identification of FoxO signaling as a promising prognostic and immunotherapeutic biomarker in glioma

Yuetao Wen, Ya He, Jingang Li, Hui Zhou, Fei Wang, Tao Xu, Yangmei Chen, Xiaolan Yang

Journal of Neuropathology & Experimental Neurology · 2026

DOI: 10.1093/jnen/nlag059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2026. Verfasst von Yuetao Wen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Glioma, Signal Transduction, Biomarkers, Tumor, Forkhead Transcription Factors. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Convincing evidence suggests that FoxO signaling (FS) dysfunction is associated with cancer progression and tumorigenesis but its effect on the tumor microenvironment (TME) and immunotherapy response remains unclear. Here, we retrieved FS-related genes from the KEGG database, first analyzing their differential expression in 31 TCGA cancer types with matched Genotype-Tissue Expression (GTEx) normal tissue data. We then calculated FS scores via ssGSEA for 33 TCGA cancer types, systematically exploring their prognostic value and correlations with TME characteristics and immunotherapy response. High FS scores were consistently associated with an immunosuppressive TME and poorer OS across multiple tumor types. Analysis of the IMvigor210 immunotherapy cohort further revealed elevated FS scores correlated with anti-PD-1 treatment resistance. Focusing on gliomas, we identified FS-based molecular subtypes and constructed a PCA score that robustly predicted glioma prognosis and immune checkpoint inhibitor response. External validation was achieved in independent CGGA and GEO cohorts. Our findings indicate that FS is a key modulator of the immunosuppressive TME and support FS and PCA scores as potential prognostic and immunotherapeutic biomarkers for gliomas with their clinical utility pending experimental validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaSignal TransductionBiomarkers, TumorForkhead Transcription FactorsBrain NeoplasmsHumansPrognosisTumor MicroenvironmentImmunotherapy

Stichwörter der Autor:innen

FoxO signalinggliomaimmunotherapyprognosistumor immune microenvironment

Substanzen

Biomarkers, TumorForkhead Transcription Factors

Autor:innen und Institutionen

  • Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Neurosurgery, Chongqing University Jiangjin Hospital, Chongqing, China.
  • Department of Physical Examination Center, Chongqing University Jiangjin Hospital, Chongqing, China.

Zitieren

APA

Wen, Y., He, Y., Li, J., Zhou, H., Wang, F., Xu, T., Chen, Y., & Yang, X. (2026). Comprehensive identification of FoxO signaling as a promising prognostic and immunotherapeutic biomarker in glioma. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlag059

Vancouver

Wen Y, He Y, Li J, Zhou H, Wang F, Xu T, et al. Comprehensive identification of FoxO signaling as a promising prognostic and immunotherapeutic biomarker in glioma. Journal of Neuropathology & Experimental Neurology. 2026. doi:10.1093/jnen/nlag059

BibTeX
@article{Wen2026,
  author = {Wen, Yuetao and He, Ya and Li, Jingang and Zhou, Hui and Wang, Fei and Xu, Tao and Chen, Yangmei and Yang, Xiaolan},
  title = {Comprehensive identification of FoxO signaling as a promising prognostic and immunotherapeutic biomarker in glioma},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2026},
  doi = {10.1093/jnen/nlag059}
}
Kostenlos starten →